MEDEXUS PHARMACEUTICALS INC (MDP.CA) Fundamental Analysis & Valuation
TSX:MDP • CA58410Q2036
Current stock price
3.15 CAD
+0.06 (+1.94%)
Last:
This MDP.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MDP.CA Profitability Analysis
1.1 Basic Checks
- In the past year MDP has reported negative net income.
- MDP had a positive operating cash flow in the past year.
- In multiple years MDP reported negative net income over the last 5 years.
- In multiple years MDP reported negative operating cash flow during the last 5 years.
1.2 Ratios
- MDP has a better Return On Assets (-0.18%) than 69.70% of its industry peers.
- MDP has a better Return On Equity (-0.52%) than 69.70% of its industry peers.
- MDP's Return On Invested Capital of 3.02% is fine compared to the rest of the industry. MDP outperforms 72.73% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for MDP is in line with the industry average of 9.22%.
- The last Return On Invested Capital (3.02%) for MDP is well below the 3 year average (9.89%), which needs to be investigated, but indicates that MDP had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROIC | 3.02% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
- MDP's Operating Margin of 3.91% is fine compared to the rest of the industry. MDP outperforms 75.76% of its industry peers.
- Looking at the Gross Margin, with a value of 53.87%, MDP belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
- In the last couple of years the Gross Margin of MDP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. MDP.CA Health Analysis
2.1 Basic Checks
- MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for MDP has been increased compared to 1 year ago.
- Compared to 5 years ago, MDP has more shares outstanding
- The debt/assets ratio for MDP has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 0.65, we must say that MDP is in the distress zone and has some risk of bankruptcy.
- MDP has a Altman-Z score of 0.65. This is in the better half of the industry: MDP outperforms 66.67% of its industry peers.
- MDP has a debt to FCF ratio of 1.48. This is a very positive value and a sign of high solvency as it would only need 1.48 years to pay back of all of its debts.
- MDP has a better Debt to FCF ratio (1.48) than 90.91% of its industry peers.
- A Debt/Equity ratio of 0.35 indicates that MDP is not too dependend on debt financing.
- MDP's Debt to Equity ratio of 0.35 is in line compared to the rest of the industry. MDP outperforms 51.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Altman-Z | 0.65 |
ROIC/WACC0.33
WACC9.11%
2.3 Liquidity
- MDP has a Current Ratio of 1.12. This is a normal value and indicates that MDP is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.12, MDP is doing worse than 75.76% of the companies in the same industry.
- MDP has a Quick Ratio of 1.12. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of MDP (0.62) is worse than 78.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 |
3. MDP.CA Growth Analysis
3.1 Past
- MDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -112.14%.
- Looking at the last year, MDP shows a decrease in Revenue. The Revenue has decreased by -9.23% in the last year.
- The Revenue has been growing slightly by 7.82% on average over the past years.
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
3.2 Future
- The Earnings Per Share is expected to grow by 53.29% on average over the next years. This is a very strong growth
- MDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.80% yearly.
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. MDP.CA Valuation Analysis
4.1 Price/Earnings Ratio
- MDP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 7.04, the valuation of MDP can be described as very cheap.
- Based on the Price/Forward Earnings ratio, MDP is valued cheaper than 84.85% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 22.51, MDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.04 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 90.91% of the companies listed in the same industry.
- MDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDP is cheaper than 90.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.29 | ||
| EV/EBITDA | 6.17 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as MDP's earnings are expected to grow with 109.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y101%
EPS Next 3Y109.18%
5. MDP.CA Dividend Analysis
5.1 Amount
- MDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MDP.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:MDP (3/26/2026, 7:00:00 PM)
3.15
+0.06 (+1.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2026-02-11/amc
Earnings (Next)N/A N/A
Inst Owners0.65%
Inst Owner ChangeN/A
Ins Owners7.65%
Ins Owner ChangeN/A
Market Cap101.74M
Revenue(TTM)99.43M
Net Income(TTM)-272.00K
Analysts82.5
Price Target7.03 (123.17%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.21%
Min EPS beat(2)0.99%
Max EPS beat(2)107.43%
EPS beat(4)4
Avg EPS beat(4)77.72%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)7
Avg EPS beat(8)78.39%
EPS beat(12)9
Avg EPS beat(12)100.87%
EPS beat(16)11
Avg EPS beat(16)73.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.29%
Revenue beat(4)0
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)-0.29%
Revenue beat(8)2
Avg Revenue beat(8)-0.34%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)0.69%
PT rev (1m)11.09%
PT rev (3m)11.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)85.71%
EPS NY rev (3m)81.82%
Revenue NQ rev (1m)1.73%
Revenue NQ rev (3m)1.19%
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.04 | ||
| P/S | 0.74 | ||
| P/FCF | 4.29 | ||
| P/OCF | 4.24 | ||
| P/B | 1.41 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.17 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.45
Fwd EY14.19%
FCF(TTM)0.73
FCFY23.33%
OCF(TTM)0.74
OCFY23.61%
SpS4.26
BVpS2.24
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROCE | 4.2% | ||
| ROIC | 3.02% | ||
| ROICexc | 3.61% | ||
| ROICexgc | 107.26% | ||
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% | ||
| FCFM | 17.26% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 2.1% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 1.57 | ||
| Cash Conversion | 127.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | 0.65 |
F-Score5
WACC9.11%
ROIC/WACC0.33
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
EBIT growth 1Y-74.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.75%
EBIT Next 3Y62.94%
EBIT Next 5Y44.59%
FCF growth 1Y-17.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.2%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MDP.CA.
What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a valuation rating of 6 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 5 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.